Profile data is unavailable for this security.
About the company
GNI Group Ltd is a Japan-based company engaged in pharmaceutical business and medical device business. The Company conducts global pharmaceutical research and development, manufacturing and distribution and biomaterials business. The Company operates in two business segments. The Pharmaceuticals segment conducts research and development, manufacturing, and sale of developed compounds, including ETUARY sold in the China market and Hydronidone (F351), which is in clinical trials. The main products also include other pharmaceuticals and reagents. The Medical Devices segment develops, manufactures, and sells medical devices such as biomaterials in the United States. This segment also includes medical device Designated Marketing Authorization Holder (DMAH) and In-Country Caretaker (ICC) services. The Company also conducts clinical and business development in the United States and conducts clinical development of F351 for Metabolic Dysfunction-Associated Steatohepatitis in the United States.
- Revenue in JPY (TTM)26.84bn
- Net income in JPY-4.41bn
- Incorporated2001
- Employees867.00
- LocationGNI Group Ltd3F, Nihonbashi-Honcho YS Bldg2-2-2, Nihonbashi Hon-choCHUO-KU 103-0023JapanJPN
- Phone+81 362143600
- Fax+81 362143668
- Websitehttps://www.gnipharma.com/
Mergers & acquisitions
| Acquired company | 2160:TYO since announced | Transaction value |
|---|---|---|
| ZOO LABO Co Ltd | 4.85% | 9.30m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heartseed Inc | -100.00bn | -100.00bn | 45.49bn | 39.00 | -- | 6.32 | -- | -- | -- | -- | -- | 314.76 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.15 | -- | 0.00004 | -- | -- | -- | -- | -- | -- | -- |
| Healios KK | 104.00m | -2.22bn | 51.57bn | 65.00 | -- | 9.04 | -- | 495.87 | -25.70 | -25.70 | 0.9661 | 42.25 | 0.0067 | -- | 0.4952 | -- | -14.27 | -23.01 | -18.09 | -30.33 | -109.62 | -- | -2,143.27 | -2,221.73 | -- | -- | 0.5993 | -- | -81.43 | 30.96 | 47.65 | -- | -11.70 | -- |
| Shin Nippon Biomedical Laboratories Ltd | 31.37bn | 3.99bn | 69.90bn | 1.44k | 17.52 | 1.32 | 9.82 | 2.23 | 95.84 | 95.84 | 753.61 | 1,269.67 | 0.2983 | 1.01 | 5.59 | 21,848,400.00 | 3.73 | 9.90 | 5.31 | 14.82 | 51.59 | 52.68 | 12.50 | 23.35 | 0.6308 | -- | 0.4383 | 30.49 | 22.55 | 17.36 | -10.96 | 14.07 | 54.79 | 58.49 |
| 3-D Matrix Ltd | 8.47bn | 6.47m | 73.58bn | 114.00 | -- | 18.45 | 96.11 | 8.69 | -2.67 | -2.67 | 71.61 | 32.90 | 1.25 | 0.9849 | 4.61 | 74,276,300.00 | 0.0958 | -35.52 | 0.1222 | -46.12 | 68.67 | 59.66 | 0.0764 | -55.66 | 2.53 | -- | 0.2619 | -- | 51.11 | 59.47 | -878.94 | -- | -7.64 | -- |
| Takara Bio Inc | 44.15bn | -7.20bn | 114.52bn | 1.78k | -- | 1.13 | -- | 2.59 | -59.79 | -59.79 | 366.64 | 839.16 | 0.3535 | 1.48 | 5.49 | 24,816,750.00 | -5.73 | 8.66 | -6.12 | 9.70 | 53.99 | 63.76 | -16.20 | 17.16 | 3.83 | -4.82 | 0.0898 | 31.40 | 3.53 | 5.44 | -29.59 | -22.88 | 20.46 | 16.27 |
| GNI Group Ltd | 26.84bn | -4.41bn | 143.66bn | 867.00 | -- | 2.86 | -- | 5.35 | -80.69 | -80.69 | 511.58 | 900.92 | 0.3447 | 2.18 | 4.01 | -- | -9.40 | 0.5414 | -11.37 | 0.6475 | 74.49 | 80.97 | -27.26 | 1.28 | 3.79 | -2.99 | 0.0941 | -- | 13.67 | 22.39 | -501.65 | -- | 34.24 | -- |
| SanBio Co Ltd | 0.00 | -3.44bn | 176.04bn | 29.00 | -- | 330.15 | -- | -- | -48.26 | -48.26 | 0.00 | 6.83 | 0.00 | -- | -- | 0.00 | -138.65 | -47.32 | -177.12 | -57.01 | -- | -- | -- | -- | -- | -12.42 | 0.725 | -- | -- | -- | -9.02 | -- | -46.04 | -- |
| Peptidream Inc | 18.52bn | -3.75bn | 203.92bn | 621.00 | -- | 3.93 | -- | 11.01 | -28.99 | -28.99 | 143.24 | 398.78 | 0.2182 | 3.75 | 3.32 | -- | -4.42 | 8.02 | -5.86 | 9.72 | 40.61 | 64.82 | -20.24 | 18.77 | 1.53 | -16.77 | 0.2485 | 0.00 | -60.32 | 9.66 | -124.97 | -- | 24.52 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Zennor Asset Management LLPas of 12 Feb 2026 | 2.14m | 3.84% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 745.29k | 1.34% |
| Simplex Asset Management Co., Ltd.as of 05 Feb 2026 | 271.50k | 0.49% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 264.40k | 0.48% |
| FIL Investments (Japan) Ltd.as of 31 Dec 2025 | 262.79k | 0.47% |
| BlackRock Advisors (UK) Ltd.as of 05 Feb 2026 | 158.90k | 0.29% |
| Asset Management One Co., Ltd.as of 16 Sep 2025 | 140.00k | 0.25% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 120.60k | 0.22% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 81.90k | 0.15% |
| Rheos Capital Works, Inc. (Investment Management)as of 18 Nov 2024 | 70.00k | 0.13% |
